tumor specificity Articles
-
A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia (Clinical Cancer Research)
Purpose:Although considerable progress has been made withautologous T cell–based therapy in B-cell malignancies, appli-cation in chronic lymphocytic leukemia (CLL) lags behind dueto disappointing response rates as well as substantial toxicitythat is of particular concern in the elderly CLL population.Vg9Vd2-T cells form a conserved T-cell subset with strongintrinsic immunotherapeutic ...
-
Ozette’s computationally-driven analysis aids advancement of cancer drug development - Case study
Summary Inflammation is a hallmark of the tumor microenvironment and an area of active investigation. To better understand how tumor inflammation differs from general inflammation, such as in gum disease, Drs. Prilic, Mair, and Erikson employed novel methods, which included high parameter flow cytometry and Ozette’s foundational technology–full annotation using ...
-
Antibody Selection for ADC Drugs
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
By BOC Sciences
-
Targeted Therapy of Intracellular Oncoproteins by Peptide-centered CAR T Cells
Researchers at the Children's Hospital of Philadelphia (CHOP) have made a breakthrough in the treatment of aggressive solid cancers, and they have developed a new cancer treatment that targets proteins within tumor cells that are essential for tumor growth and survival, but this has not been possible before. Using the power of large data and advanced computational methods, researchers can ...
-
The ins and outs of TCR-T cell therapy
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
-
Mesothelin: A New Target for Cancer Therapy
Structure and function of mesothelin The MSLN gene is located in chromosome 16p13. It contains 17 exons, with a cDNA length of about 2138bp, has a 1884-bp open reading frame, and encodes the precursor protein of 628 amino acids (69 kDa). This precursor protein can be hydrolyzed by furin protease into two parts: mesothelin in the size of 40 kDa fragments and 31 kDa secreted fragments called ...
By BOC Sciences
-
Cancer Target: Mesothelin
Mesothelin is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein. Its biological function has not yet been clarified, but due to its limited distribution in normal tissues and high expression in some tumor tissues, it is expected to be used in tumor-specific treatment. In existing studies of human epidermoid carcinoma cell lines expressing mesothelin, biodistribution analysis ...
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
Cytokines in CAR-T Cell Therapy
What is CAR T-cell therapy? Car-t cell therapy involves genetically engineering T cells isolated from patients or allogeneic donors to express chimeric antigen receptors (CAR) that specifically recognize and kill tumor cells. As a "living" drug, CAR-T therapy is very different from traditional drugs. It is a new type of precision targeted therapy for the treatment of tumors. Compared with ...
-
Optimization of Three Elements of ADC Drugs
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. The link between the antibody and linker is controlled by the coupling method, which determines the DAR value of the drug and affects the stability and PK ...
-
Antibody-Drug Conjugates: New Strategies of ADC Payloads
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal antibodies, that the era of ADC drug development truly began. Driven by increasingly mature technology, ADC drugs have gone through three iterations (Fig. 1). Although ADCs have gone through three iterations, current ...
By BOC Sciences
-
Indication selection for anti-PDx combination therapy In collaboration with big pharma - Case Study
The Challenge: One of the most common challenges in immuno-oncology is identifying the indications and patient populations that would benefit from a specific therapy, especially on top of Standard of Care (SOC) treatments. Our platform tackled this challenge of indication prioritization and patient stratification for a combination of a specific target (A) with an anti-PDX drug that one of our ...
By CytoReason
-
Science: Knockout of this epigenetic gene gives CAR-T cells the ability to continuously attack cancer cells
Simply put, CAR-T is to transform the patient's immune T cells in vitro by biotechnology, so that they recognize antigens on the surface of tumor cells, and then inject these cells back into the patient to achieve the therapeutic effect of recognizing and killing cancer cells. In 2017, CAR-T therapy was first approved by the FDA for the treatment of blood cancers such as leukemia and lymphoma. ...
-
Applications of Cell-penetrating Peptides
Cell-penetrating peptides (CPPs) are short peptides that facilitate cellular intake and uptake of molecules ranging from nano-size particles to small chemical compounds to large fragments of DNA. As a versatile peptide, CPP has been widely used for diagnostic and therapeutic applications. 1. Oligo and siRNA Transport As an important means for targeted therapy of specific genes, oligonucleotides ...
-
Immune Strategies for Cancer Treatment
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
-
Research Progress of Targeted Protein Degradation Technology
The mode of action of currently developed drugs is mostly to achieve the purpose of disease treatment by inhibiting or enhancing the activity of target proteins. However, these drugs have to bind to the active site of target proteins to work. Among the known drug target proteins, only about 20% of the target proteins contain bindable active site, and 80% of the target proteins are non-druggable ...
By Profacgen
-
Mutation-directed Neo-protein-protein Interactions in Cancer
Genetic mutations in cells are an important cause of cancer development, progression, and drug resistance. How to quickly and accurately translate massive tumor genomic information into safe and effective cancer targeted therapies in clinical practice is a scientific frontier today. At present, a large number of scientific studies have focused on how oncogenic mutations regulate the activity of ...
By Profacgen
-
Bispecific Antibodies and Bispecific Antibody ADCs
With the rapid development of antibody-drug conjugate (ADC), more and more companies have entered the field of ADC research and development, and various types of ADC technologies and branches have emerged. Bispecific antibody conjugates (BsAb ADCs) are one of the emerging new technologies. The high specificity of bispecific antibodies enables more precise targeting of tumor cells. On the other ...
By BOC Sciences
-
Analytical Approaches and Applications of Whole Exome Sequencing (WES) in Oncology
Introduction Genomics has revolutionized cancer research, transforming the way we diagnose, treat, and monitor cancer. Among the powerful genetic analysis methods, Whole Exome Sequencing (WES) stands out as a cutting-edge technique that employs sequence capture technology to enrich DNA from the whole exome regions, enabling high-throughput sequencing. WES offers a simpler, more cost-effective, ...
By CD Genomics
-
CD Biosciences Launches Substrate-Chromogens for Immunohistochemistry
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, has announced the launch of its innovative line of Chromogenic Substrates for immunohistochemistry (IHC). These cutting-edge substrates offer superior signal sensitivity, long-term storage stability, enhanced safety, and user-friendliness, empowering researchers to unlock deeper insights into ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you